« Back
Murine herpesvirus 68 infection in a novel mouse model based on a  patient with RAG2 F62L/F62L mutation and combined immunodeficiency
Poster Title: Murine herpesvirus 68 infection in a novel mouse model based on a patient with RAG2 F62L/F62L mutation and combined immunodeficiency
Submitted on 09 Feb 2018
Author(s): Bence Zakota, Boglarka Ujhazi MSc, Peter Medveczky PhD, Krisztian Csomos PhD, Jolan E Walter MD PhD
Affiliations: University of South Florida, Tampa
Poster Views: 298
View poster »

Poster Information
Abstract: Objective:
Herpes virus infections are often observed prior to the onset of antibody-mediated autoimmunity among patient with hypomorphic mutations in recombination-activating genes 1 and 2 RAG1/2), especially those with late-onset combined immunodeficiency. The aims of our studies were to examine if viral infections can trigger autoreactivity in models with hypomorphic mutations in their recombination activating genes 1 and 2 (RAG1/2). 

Novel murine strain with rag2F62L/F62L and rag2F62L/- were designed to model patients with combined immunodeficiency secondary to RAG mutations. Mutant and wild type mice were infected with murine gammaherpesvirus-68 (MHV-68) and monitored for response to the virus 
and autoantibody generation, anti-viral antibody and cellular response for weeks after infection. 

All rag2F62L/F62L and rag2F62L/- and wild type mice had responded with antibody 
production to virus and self antigens after MHV68 infection. However, mice with hypomorphic rag mutation developed increased and sustained autoantibody levels compared to wild type mice. 

MHV-68 infection in hypomophic rag2 mouse models induce increased antibody production to irus and self, suggesting polyclonal activation of autoreactive B cells and break in B cell tolerance. These findings allow mechanistic insight to the development of autoimmunity in the setting of viral infections among patients with primary immunodeficiencies. 
Summary: Herpes virus infections have been observed prior to onset of autoimmunity in patients with only partial activity of recombination-activating genes 1 and 2 (RAG 1/2). In this study, we examined the effects of murine gammaherpesvirus-68 on the immune system of novel RAG 1/2 deficient mice designed to model human patients with partial RAG 1/2 activity.References: Corneo B, Moshous D, Güngör T, Wulffraat N, Philippet P, Le Deist FL, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. (2001) 97(9): 2772–6.

Ehl S, Schwarz K, Enders A, Duffner U, Pannicke U, Kuhr J, et al A variant of SCID with specific immune responses and predominance of gamma delta T cells. J Clin Invest. (2005) 115:3140–8.

Dalal I, Tabori U, Bielorai B, Golan H, Rosenthal E, Amariglio N, et al. Evolution of a T-B- SCID into an Omenn syndrome phenotype following parainfluenza 3 virus infection. Clin. Immunol. (2005) 115:70-73.

Walter JE, Rosen LB, Csomos K, Rosenberg JM, Mathew D, Keszei M, et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest (2015) 125(11):4135–48.
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

VITVO: Mimicking In Vivo Complexity By The Innovative 3D Model
Olivia Candini1, Giulia Grisendi1, Elisabetta Manuela Foppiani1, Matteo Brogli1, Beatrice Aramini2, Valentina Masciale3, Carlotta Spano1, Tiziana Petrachi4, Elena Veronesi4, Pierfranco Conte5,6, Giorgio Mari1 & Massimo Dominici1,3

Cancer Vaccine, Your T-cell guru: A Bioengineering Approach for Cancer Therapy
Zaween Hanis Bt Mohamad Shamsul, Sam Pei Fong, Chin Chin Liew, Chia Jin Chuah, Turgaa Shini Devaraj, Nur’Awatif Ishak, Sheng Keat Siah, Muhammad Nur Syazwan Md Zin, Kar Cheng Wong

What are HIV and AIDS
Karwan M. Qadr and Abdulla Azad

Multiplex miRNA Profiling for Biomarker Discovery and Verification Studies Using the FirePlex® Platform
M. Tackett, B. Heinrich, I. Diwan, G. Tejada, C. Rafferty, E. Atabakhsh, and D. Pregibon

Accelerating high-throughput screening with FirePlex®-HT:An automatable, multiplex immunoassay using FirePlex® Particle Technology
A. Perea, B. Heinrich, W. Austin, C. Rafferty, M. Camilleri, L. To, E. Atabakhsh, and D. Pregibon